Antifungal resistance – Page 3

Pathogenic mucorales: Deciphering their cell wall polysaccharidome and immunostimulatory potential

mycolabadmin

Mucormycosis is a dangerous fungal infection that kills many immunocompromised patients. Researchers analyzed the outer layer (cell wall) of three common disease-causing fungi and discovered that their surfaces contain sugar-like molecules that trigger strong inflammatory responses from the immune system. This excessive inflammation may actually contribute to the disease’s severity, suggesting that controlling inflammation alongside antifungal treatment might improve patient outcomes.

Informing the World Health Organization Fungal Priority Pathogens List (WHO-FPPL): A collection of systematic reviews

mycolabadmin

The World Health Organization created a priority list of dangerous fungal infections affecting millions of people globally each year. Experts reviewed 19 different fungal pathogens and ranked them by how dangerous they are and how much they need research and treatment development. The list identifies which fungal infections should get the most attention from doctors, researchers, and public health officials to improve patient outcomes and reduce deaths.

John Perfect Shares Insights on Infectious Diseases, Antifungal Therapy, and Drug Resistance

mycolabadmin

Dr. John Perfect, a leading expert in fungal infections, shares his 48 years of experience studying infectious diseases, particularly focusing on Cryptococcus and candida infections. He discusses how antifungal medications have evolved from highly toxic drugs to more effective treatments, while emphasizing the need for faster-acting drugs that require shorter treatment periods. The interview covers emerging diagnostic tools using molecular methods, the promise of combining drugs with immune-boosting therapies, and the importance of understanding how fungi survive in the human body to develop better treatments.

Functional Amyloids in Adhesion of Non-albicans Candida Species

mycolabadmin

Candida fungi cause common infections and form tough biofilms that resist treatment. These fungi stick to body surfaces using proteins called adhesins that form amyloid-like structures. Researchers found that special peptides can block these amyloid structures in several Candida species, preventing them from sticking to cells and potentially offering a new way to fight these infections.

Clinical Significance and Therapeutic Challenges of Scedosporium spp. and Lomentospora prolificans Isolates in a Single-Center Cohort of Lung Transplant Recipients

mycolabadmin

This study examined dangerous fungal infections caused by Scedosporium and Lomentospora species in lung transplant patients at a Spanish hospital. Researchers found these infections were uncommon but very serious, with high death rates especially from the Lomentospora type. Current antifungal drugs often don’t work well against these fungi, highlighting the need for better treatment options.

Breaking down biofilms across critical priority fungal pathogens: proteomics and computational innovation for mechanistic insights and new target discovery

mycolabadmin

This comprehensive review examines how scientists are fighting dangerous fungal infections that form protective biofilms resistant to current antifungal drugs. Researchers are using advanced protein analysis techniques (proteomics) and artificial intelligence-based computational tools to identify new targets for drug development against four critical fungal pathogens that cause life-threatening infections like meningitis and lung infections. By combining these technologies, scientists can better understand how these fungal biofilms form and develop more effective treatments.

Epidemiology of Candidemia, Candiduria and Emerging Candidozyma (Candida) auris Across Gulf Cooperative Council Countries and Yemen in the Arabian Peninsula

mycolabadmin

This comprehensive review examines fungal bloodstream and urinary tract infections caused by Candida species across Middle Eastern countries. The study shows that while Candida albicans remains common, dangerous antibiotic-resistant strains like Candidozyma auris are increasingly appearing in hospitals. The research highlights that better diagnostic tools and infection prevention practices are urgently needed in the region to protect patients and reduce deaths from these serious infections.

Prevalence and antifungal susceptibility profiles of Candida isolates among patients with candiduria: a multiplex PCR assay

mycolabadmin

Researchers studied yeast infections in urine from hospitalized patients using advanced molecular testing. They found that while Candida albicans was most common, other yeast species were becoming more resistant to antifungal medications. The study used a 21-tube PCR test to identify different yeast species and tested which medications worked best against them. Results showed that newer yeast species were much more likely to resist commonly used antifungal drugs like fluconazole.

Overexpression of efflux pump and biofilm associated genes in itraconazole resistant Candida albicans isolates causing onychomycosis

mycolabadmin

Researchers studied why some fungal nail infections caused by Candida albicans stop responding to the antifungal drug itraconazole. They found that resistant fungal cells have higher activity of genes that pump the drug out of cells and produce slimy protective coatings called biofilms. These resistant fungi also formed less dense biofilms when the drug was present from the start. Understanding these resistance mechanisms could help develop new treatments by targeting the pump systems or breaking down the protective biofilm layers.

Clinical aspects and recent advances in fungal diseases impacting human health

mycolabadmin

Fungal infections are becoming a major health threat, affecting over a billion people worldwide. The main problems are difficulty diagnosing these infections, increasing resistance to current medications, and limited treatment options. Doctors and the public need better awareness, and new antifungal drugs with different approaches are needed to effectively treat resistant infections.

Anti-Therapeutic Action: Antifungal resistance